KalVista Pharmaceuticals, Inc.
NASDAQ:KALV
11.18 (USD) • At close November 7, 2024
Overzicht | Financiële gegevens
Bedrijfsnaam | KalVista Pharmaceuticals, Inc. |
Symbool | KALV |
Munteenheid | USD |
Prijs | 11.18 |
Beurswaarde | 483,149,290 |
Dividendpercentage | 0% |
52-weken bereik | 7.21 - 16.88 |
Industrie | Biotechnology |
Sector | Healthcare |
CEO | Mr. Thomas Andrew Crockett M.B.A. |
Website | https://www.kalvista.com |
An error occurred while fetching data.
Over KalVista Pharmaceuticals, Inc.
KalVista Pharmaceuticals, Inc., a clinical stage pharmaceutical company, discovers, develops, and commercializes small molecule protease inhibitors for diseases with unmet needs. The company's product portfolio comprises small molecule plasma kallikrein inhibitors targeting hereditary angioedema (HAE) and diabetic macular edema (DME); and oral plasma kallikrein inhibitors. Its products include KVD001, a
Vergelijkbare Aandelen
Financiële Gegevens
Cijfers zijn in miljoenen (USD)
Cijfers zijn in miljoenen (USD)